# US 10,441,566 B2 · Use of butylidenephthalide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,566 B2
- Document ID: US10441566B2
- Status: Granted
- Kind: B2
- Application number: 16/068,257
- Filed: 2016-01-07
- Published: 2019-01-10
- Granted: 2019-10-15
- Earliest claimed: 2016-01-07
- Assignees: Everfront Biotech Inc.
- Applicants: Everfront Biotech Inc.
- Inventors: Horng-Jyh Harn; Shinn-Zong Lin
- Web page: https://patentgrep.com/patent/US10441566B2

## CPC

- A61K 31/365: Lactones
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is the use of an active ingredient in the manufacture of a medicament, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt of butylidenephthalide, and combinations thereof, and wherein the medicament is used for the prevention and/or treatment of oral submucous fibrosis (OSF) and may be used in the form of an injection lozenge, oral solution, or smearing preparation.

## Claims

### Claim 1

A method for treating oral submucous fibrosis (OSF), comprising administering to a subject in need an effective amount of an active ingredient, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt of butylidenephthalide, and combinations thereof.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the active ingredient is administered as an injection, a tablet, an oral liquid, or a smearing preparation.

### Claim 3

A method for treating oral submucous fibrosis (OSF), comprising administering to a subject in need an effective amount of an active ingredient, wherein the active ingredient is selected from the group consisting of butylidenephthalide (BP), a pharmaceutically acceptable salt of butylidenephthalide, and combinations thereof, wherein the method is for at least one of inhibiting epithelial-mesenchymal transition (EMT) of oral submucosal tissue cells, inhibiting the abilities of oral submucosal tissue cells to crawl and invade, inhibiting oral submucosal tissue cells to differentiate into myofibroblasts, inhibiting the activation of myofibroblasts, and inhibiting the contraction of extracellular matrix in oral submucosal tissues.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein the active ingredient is administered as an injection, a tablet, an oral liquid, or a smearing preparation.